Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.4
3 insiders sold shares within a month
Since Aug 26, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 50 (planned)
- Started
- Jan 16, 2026
- Main results expected
- Sep 2026
- Fully finished
- Jan 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Patients With 1 or More Adverse Event
Measured over: From first dose of study treatment up to 28 days after final dose, assessed up to 9 months
Number of Patients With 1 or More Serious Adverse Events
Measured over: From first dose of study treatment up to 28 days after final dose, assessed up to 9 months
Number of Patients With 1 or More Adverse Events Leading to Study Drug Discontinuation
Measured over: From first dose of study treatment up to final dose, assessed up to 9 months
Percent of Patients who Experience Dose Limiting Toxicity (DLT)
Measured over: Up to 28 days after initiation of Cycle 1 (each cycle consists of 28 days)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 4.4, since 2026-08-26, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07276373 · record last updated 2026-08-19 · checked 2026-11-09 15:42 UTC